Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960043/S137

Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System

Abbott Vascular, Inc. · Decision date Sep 24, 2026

MEDTECHLEDGER EXPLANATIONP960043/S137

What did the FDA decide?

The FDA recorded a 30-day notice decision, OK30, dated 2026-09-24, for P960043/S137, a supplement to Abbott Vascular, Inc.'s Perclose ProGlide Suture-Mediated Closure System and Perclose ProStyle Suture-Mediated Closure and Repair System. The listed supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier, and the recorded statement describes automation of the existing suture trimmer manufacturing process.

The notice concerns manufacturing of the suture trimmer component rather than a new clinical indication or a new approval of the full closure systems. The source record lists the device category as vascular hemostasis, specialty Cardiovascular and product code MGB. No supporting documents, document record identifier or review detail beyond the notice fields is present, so the scope of the process change and any effect on finished device performance remain unstated in this record.

The decision code OK30 is reported as given; its precise regulatory meaning is not defined in the source data and is not interpreted here.

FDA approval order statement

automation of existing suture trimmer manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P960043/S137
Regulatory pathway
PMA supplement
Product code
MGB
Decision code
OK30
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

For the original device and its historical approval scope, see PMA P960043. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P960043 · Original PMA

    PROSTAR 9 FR. PERCUTANEOUS VASCULAR SURGICAL (PVS) SYSTEM

  2. P960043/S137 received

    Application receipt date recorded by FDA.

  3. P960043/S137 · FDA decision

    30-Day Notice

  4. P960043/S138 · Related supplement

    Perclose ProStyle Suture-Mediated Closure and Repair System

  5. P960043/S139 · Related supplement

    Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System

Timeline entries are records held by MedtechLedger for P960043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960043

Explore the linked device profile

Other records with product code MGB

Product / regulatory recordCompanyPathwayDecision dateSource
Vasorum, Ltd.PMA supplementOct 30, 2026FDA
Vivasure Medical , Ltd.PMA approvalOct 16, 2026FDA
Cardiva Medical, Inc.PMA supplementSep 10, 2026FDA
Vasorum, Ltd.PMA approvalJul 20, 2016FDA
Cardiva Medical, Inc.PMA approvalJan 31, 2013FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Saginaw Dr., Redwood, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records